Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Birgitta Schweickert has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kinetic Patterns of Antibiotic Consumption in German Acute Care Hospitals from 2017 to 2023

    by Birgitta Schweickert, Niklas Willrich, Marcel Feig, Marc Schneider, Michael Behnke, Luis Alberto Peña Diaz, Christine Geffers, Imke Wieters, Karin Gröschner, Doreen Richter, et al.

    Background: Antimicrobial consumption (AMC) patterns, besides prescribing behaviors, reflect the changing epidemiology of infectious diseases. Routine surveillance data have been used to investigate the development of AMC from 2017 to 2023 and the impact of COVID-19 within the context of the framing time periods. Methods: Data from 112 hospitals, continuously participating from 2017 to 2023 in the national surveillance system of hospital antimicrobial consumption based at the Robert Koch Institute, were analyzed according to the WHO ATC (Anatomical Therapeutic Chemical)/DDD (Defined Daily Dose) method and categorized according to the WHO AWaRe-classification. AMC was quantified by consumption density (CD) expressed in DDD/100 patient days (PD) and DDD/100 admissions (AD). The time period was subdivided into three phases: pre-pandemic phase (2017–2019), main pandemic phase (2020–2021) and transition phase (2022–2023). Linear regression models have been used to determine the presence of an overall trend, the change in intra-phasic trends and phase-specific mean consumption levels over time. Results: From 2017 to 2023 total antibiotic consumption decreased by 7% from 57.1 to 52.9 DDD/100 PD. Four main kinetic patterns emerged across different antibiotic classes: Pattern 1 displays a decreasing pre-pandemic trend, which slowed down throughout the pandemic and transition phase and was exhibited by second-generation cephalosporins and fluoroquinolones. Pattern 2 reveals a rising pre-pandemic trend, which decelerated in the pandemic phase and accelerated again in the transition phase and was expressed by aminopenicillins/beta-lactamase inhibitors, beta-lactamase sensitive pencillins, azithromycin and first-generation cephalosporins. Pattern 3 shows elevated mean consumption levels in the pandemic phase exhibited by carbapenems, glycopeptides, linezolid and third-generation cephalosporins. Pattern 4 reveals a rising trend throughout the pre-pandemic and pandemic phase, which reversed in the transition phase without achieving pre-pandemic levels and was expressed by beta-lactamase resistant penicillins, daptomycin, fosfomycin (parenteral) and ceftazidime/avibactam. Conclusions: Kinetic consumption patterns across different antibiotic classes might reflect COVID-19-related effects and associated changes in the epidemiology of co-circulating pathogens and health care supply. Broad-spectrum antibiotics with persisting elevated consumption levels throughout the transition phase require special attention and focused antimicrobial stewardship activities.


  • Open Access

    Infektionsschutz und Impfsurveillance in der Langzeitpflege

    by Dunja Said, Muna Abu Sin, Arina Zanuzdana, Birgitta Schweickert, Tim Eckmanns

    Zusammenfassung: Die Steigerung der Lebenserwartung und der damit wachsende Anteil an Personen hohen Alters hat in den letzten Jahren in Deutschland zu einem zunehmenden Anteil an pflegebedürftigen Menschen geführt (Statistisches Bundesamt 2022). Nach Angaben des Statistischen Bundesamtes beträgt die Anzahl der Pflegebedürftigen derzeit ca. 4,1 Mio, wobei mit rund 80 % der überwiegende Anteil zu Hause, entweder durch Angehörige (51,3 %) oder ambulante Pflege- und Betreuungsdienste (23,8 %) bzw. eine Kombination von beidem, versorgt wird, während die anderen 20 % vollstationär in einem der 15.000 Alten- und Pflegeheime untergebracht sind (Statistisches Bundesamt 2020, 2022).Insbesondere die Bewohnenden dieser Einrichtungen gehören zu den Hochrisikogruppen für einen schweren oder tödlichen Verlauf von Infektionskrankheiten wie Covid-19. Der Vulnerabilität liegen verschiedene Faktoren zugrunde, wie Gebrechlichkeit und Immunschwäche sowie Komorbiditäten, insbesondere Herz-Kreislauf-Erkrankungen, Diabetes oder Demenz. In Altenheimen leben darüber hinaus auch besonders häufig hochaltrige Personen ab 80 Jahren, die z. B. in Kombination mit einer Demenzerkrankung zwei wesentliche Risikofaktoren für einen tödlichen Covid-19-Verlauf vereinen (España et al. 2021).

  • Surveillance des Antibiotikaverbrauchs in Krankenhäusern

    by B. Schweickert, T. Eckmanns, S. Bärwolff, N. Wischnewski, E. Meyer

    Durch das „Gesetz zur Änderung des Infektionsschutzgesetzes und anderer Gesetze“ vom 28. Juli 2011 (BGBL. I S. 1622) wurde die Verpflichtung von Leitern von Krankenhäusern und von Einrichtungen für ambulantes Operieren zur Überwachung von Erregern mit besonderen Resistenzen und von Krankenhausinfektionen auf das kontinuierliche Monitoring des Antibiotikaverbrauchs ausgeweitet (§ 23 Abs. 4 Satz 2 des Infektionsschutzgesetzes). Hiermit wurde der Bedeutung des umsichtigen Einsatzes von Antibiotika zur Verhütung und Bekämpfung von resistenten Krankheitserregern Rechnung getragen. Das Gesundheitsamt kann zur Überwachung der Einhaltung der gesetzlichen Bestimmungen Einsicht in die betreffenden Unterlagen verlangen. Ein Anliegen des vorliegenden Beitrages ist es, die Gesundheitsämter in dieser Aufgabe zu unterstützen. Es werden Hintergrundinformationen zur Antibiotika-Verbrauchs-Surveillance (AVS) und deren Bedeutung insbesondere im Rahmen der Umsetzung einer rationalen Antibiotikatherapie gegeben und Kriterien vorgestellt, die für eine Überwachung der Implementierung der AVS im Krankenhaus zweckmäßig erscheinen. Darüber hinaus werden Vorschläge zur konkreten Vorgehensweise gemacht und Möglichkeiten und Grenzen der Tätigkeit des Gesundheitsamtes im Bereich AVS angesprochen. According to the German Protection Against Infection Act (IfSG; section 23 paragraph 4, July 2011), hospitals and clinics for ambulatory surgery are obliged to establish a continuous monitoring of antibiotic consumption in their institute. The introduction of the surveillance of antibiotic consumption aims to contribute to an optimization of antibiotic prescription practices in order to confine the development and spread of resistant pathogens. The local public health authority is entitled to supervise the implementation of legal requirements in the hospital setting. The main aim of this article is to support local public health authorities in coping with this task by providing background information on the surveillance of antibiotic consumption and its role as a key component of antibiotic stewardship programs. Furthermore, criteria suitable for assessing the implementation of a functioning surveillance system are proposed. The possibilities and limitations of the activities of public health authorities in this context are addressed.


  • Antibiotika-Verbrauchs-Surveillance

    by B. Schweickert, W.V. Kern, K. de With, E. Meyer, R. Berner, M. Kresken, M. Fellhauer, M. Abele-Horn, T. Eckmanns


  • MRSA-surveillance in Germany: data from the Antibiotic Resistance Surveillance System (ARS) and the mandatory surveillance of MRSA in blood

    by B. Schweickert, I. Noll, M. Feig, H. Claus, G. Krause, E. Velasco, T. Eckmanns

    Data from the German Antibiotic Resistance Surveillance system (ARS) and statutory notification of methicillin-resistant Staphylococcus aureus (MRSA) in blood cultures are presented. ARS is a voluntary laboratory-based surveillance system providing resistance data of all clinical pathogens and sample types from hospitals and ambulatory care. Statutory notification includes MRSA detected in blood and cerebrospinal fluid by microbiological laboratories. Resistance data from 2008 to 2010 and MRSA-bacteraemia incidences from 2010 are presented. From 2008 to 2010, resistance data from 70,935 Staphylococcus aureus isolates were transferred to the national health institution. MRSA proportions in hospitals and outpatient care account for 19.2% and 10.6%, respectively. In hospital care high proportions of MRSA were found in nephrological, geriatric, neurological general wards and surgical ICUs (49.4%, 45.8%, 34.2%, and 27.0%, respectively), while in community outpatient care urological practices (29.2%) account for the highest values. In both healthcare settings urinary tract samples stand out with high proportions of MRSA (hospitals, 32.9%; outpatients, 20.5%). In 2010, 3900 cases of MRSA bacteraemia were reported, accounting for an incidence of MRSA bacteraemia of 4.8/100,000 inhabitants/year. Stratification by federal states shows considerable regional differences (range, 1.0–8.3/100,000 inhabitants/year). Vulnerable areas in hospitals and outpatient care have been pointed out as subjects for further inquiries.


  • Open Access

    The MRSA-import in ICUs is an important predictor for the occurrence of nosocomial MRSA cases

    by B. Schweickert, C. Geffers, T. Farragher, P. Gastmeier, M. Behnke, T. Eckmanns, F. Schwab